effect of group counseling based on the acceptance and commitment model on the quality of sexual life and sexual function of women infected with human papilloma virus

Investigating the effect of group counseling based on the acceptance and commitment model on the quality of sexual life and sexual function of women infected with human papilloma virus

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250303064919N1

Enrollment

Registered

2025-04-12

Start date

2025-04-21

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human papillomavirus. Anogenital (venereal) warts

Interventions

Intervention 1: Intervention group: In the intervention group, 28 people from the intervention group will be divided into three groups (2 groups of 9 and one group of 10 people) and the sessions will

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Women with informed consent Be at least 18 years old Being married Having sex Clinical diagnosis of HPV by a gynecologist, dermatologist, or infectious disease specialist Persian reading and writing skills to fill out the relevant questionnaires

Exclusion criteria

Exclusion criteria: history of genital malignancy history of HPV vaccination having other sexually transmitted diseases sexual dysfunction in men (woman's statement) Physical, mental, and sexual diseases (affecting psychosocial and sexual health) and immunodeficiency diseases alcohol, drugs, and cigarettes use

Design outcomes

Primary

Measure	Time frame
The study variable includes the female sexual function score on the Female Sexual Function Index questionnaire in women infected with human papillomavirus. Timepoint: Sexual function will be measured at the beginning of the study (before the intervention begins), immediately after the completion of counseling sessions, and 1 month after the completion of counseling in women with human papillomavirus. Method of measurement: The Female's Sexual Function Index questionnaire will be used to measure the sexual function variable of women infected with human papillomavirus.	—

Measure

Time frame

The study variable includes the female sexual function score on the Female Sexual Function Index questionnaire in women infected with human papillomavirus. Timepoint: Sexual function will be measured at the beginning of the study (before the intervention begins), immediately after the completion of counseling sessions, and 1 month after the completion of counseling in women with human papillomavirus. Method of measurement: The Female's Sexual Function Index questionnaire will be used to measure the sexual function variable of women infected with human papillomavirus.

—

Secondary

Measure	Time frame
Study variables included the sexual quality of life score on the Female's Sexual Quality of Life Questionnaire in women with human papillomavirus . Timepoint: Quality of sexual life will be measured at the beginning of the study (before the intervention begins), immediately after the completion of counseling sessions, and 1 month after the completion of counseling in women with human papillomavirus . Method of measurement: The Female's Sexual Quality of Life Questionnaire will be used to measure the variable of sexual quality of life in women infected with human papillomavirus .	—

Measure

Time frame

Study variables included the sexual quality of life score on the Female's Sexual Quality of Life Questionnaire in women with human papillomavirus . Timepoint: Quality of sexual life will be measured at the beginning of the study (before the intervention begins), immediately after the completion of counseling sessions, and 1 month after the completion of counseling in women with human papillomavirus . Method of measurement: The Female's Sexual Quality of Life Questionnaire will be used to measure the variable of sexual quality of life in women infected with human papillomavirus .

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaba Mahmoudy

Oroumia University of Medical Sciences

mahmoudy.s@umsu.ac.ir+98 44 3345 4925

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026